NEWARK, Del, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The Global HPV testing and Pap Test Market was valued at US$ 2.2 Bn in 2021 and is expected to reach US$ 15 Bn by 2032, finds Future Market Insights (FMI) in a recent market survey. As per the findings of the report, Pap Testing will remain pivotal for the market as the bulk of revenue will be generated through this category, with a forecasted CAGR of 17.5%. Official strategies and policies, such as the WHO global strategy for cervical cancer elimination, are expected to boost demand for testing. New technologies, government programs, and awareness drives will help boost demand in even low-resource areas.
Cervical Cancer Screening to Continue being the key application for HPV and Pap Test Revenue
Vaginal Cancer cannot be detected with a Pap or HPV tests on their own. They can, however detect cervical cancer and HPV, and pre-cancerous conditions. This is useful since the presence of these can be precursors to cervical cancer.
Get Access To Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-15811
The US to Command the Larger Proportion of HPV testing and Pap test consumption in the Analysis Period
The US contributed the most to the demand for HPV and Pap Tests. The ACS recommends screening women over 25 at recommended intervals of time. There are also programs that provide free or cheaper testing to women such as the NBCCEDP by the CDC.
HPV testing and Pap Test Market: Competition Insights
HPV Testing and Pap Test providers are focused on increasing the efficiency, accuracy and affordability of their tests and harnessing new technology. The key companies operating include Abbott Laboratories, Qiagen N.V., Becton, Dickinson and Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific. Inc., bioMérieux SA
Customization Report Before Buying, Visit: https://www.futuremarketinsights.com/customization-available/rep-gb-15811
Some of the recent developments in HPV Testing and Pap Test are as follows:
- In June 2022, F. Hoffmann-La Roche AG, a Switzerland-based healthcare pharmaceutical and diagnostics company announced the launch of a self-sampling solution, via which patients can collect samples privately at a healthcare facility under instructions and have them analyzed. The aim of enabling self-collection was to provide an alternative to the usual invasive clinician-based collection process.
- In May 2022, Alercell, Inc, a molecular diagnostics company and provider of diagnostics announced it’s HPV DNA based test kit: "Meltpro HPV genotype test". It is based on DNA sequencing analysis. The use of a PCR machine eliminates the risk of human interpretation and provides faster results, taking under three hours.
- In June 2022, Operating in the oncology healthcare sector, Karkinos Healthcare developed CerviRaksha, a clinically validated HPV test, pre-qualified and approved by the World Health Organization (WHO) and the United States Food and Drug Administration (FDA). It was also granted the CE mark and bears the CE mark. Samples are collected at home and results are provided by email. The HPV-16 and HPV-18 genotypes are distinguished individually, and false positives are filtered.
- In May 2022, The London School of Hygiene and Tropical Medicine and the University of Manchester, and the University of Hull will collaborate to test for cervical cancer in women of the 65-and-older age group, who are often overlooked despite accounting for over 50% of cervical cancer incidents in the UK. This test will also only require a urine sample, which might encourage women who were opting out of the test to take part.
To Buy this Report Visit: https://www.futuremarketinsights.com/checkout/15811
More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the HPV Testing and Pap Test Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.
The study reveals essential insights on the basis of by Test Type (HPV Testing, Pap Test), By Application (Vaginal Cancer Screening, Cervical Cancer Screening), By Product Type (Instruments, Consumables, Services), by Technology (PCR, Immunodiagnostics, Other Technologies), across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
Complete TOC with Report Preview: https://www.futuremarketinsights.com/reports/hpv-testing-and-pap-test-market
Explore Our Trending Reports of FMI's Healthcare Market Insights Landscape
Cystatin C Testing Market Value - The global cystatin C testing market was valued at around US$ 194.3 Mn at the end of 2021. The market is projected to register a 7.5% CAGR and top a valuation of US$ 400.4 Mn by 2032.
Cardiolipin Antibodies Test Market Growth - Increase in demand for preventative diagnosis, and continuously increasing prevalence of Systemic lupus erythematous (SLE) diseases across the globe are significant factors that are anticipated to propel the global cardiolipin antibodies test market.
Cardiac Biomarker Diagnostic Test Kits Market Demand - On the basis of product type, the BNP test kit segment is expected to hold lion’s share. As per the study, the segment is expected to account for over 50% of the global market share, with sales estimated to total US$ 682.9 Mn in 2022.
Cryptococcal Antigen Lateral Flow Assay Test Market Size - The cryptococcal antigen lateral flow assay is a type of an immunechromotography test system, used to identify the capsular polysaccharide antigens of cryptococcus species present in serum and Cerebrospinal Fluid (CSF).
Network Point-of-Care Glucose Testing Market Outlook - Network Point-of-Care Glucose Testing Market by Product Type & Region - Forecast 2022 - 2032
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact Us:
Future Market Insights, Inc
Christiana Corporate,
200 Continental Drive,
Suite 401, Newark,
Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
